Skip to content
HowShorted

SkinHealth Systems Inc. Class short interest in 2023

In 2023, SkinHealth Systems Inc. Class's disclosed short interest ran from 19.31% of shares outstanding on 13 Jan 2023 to 9.89% on 29 Dec 2023, a change of -9.42 percentage points. The year's high was 19.31% on 13 Jan 2023 and its low 9.39% on 30 Nov 2023, averaging 14.61% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.21 days on 31 Jul 2023. Full history: SkinHealth Systems Inc. Class.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for SkinHealth Systems Inc. Class in 2023

2023 in figures

Start of year
19.31% (13 Jan 2023)
End of year
9.89% (29 Dec 2023)
Change
-9.42 pp
High
19.31% (13 Jan 2023)
Low
9.39% (30 Nov 2023)
Average
14.61%
Highest days to cover
16.21 (31 Jul 2023)
SEC filings marked
8

Every report in 2023

SkinHealth Systems Inc. Class short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202319.31%14.50
31 Jan 202318.30%14.74
15 Feb 202318.95%15.94
28 Feb 202316.54%6.51results (8-K)
15 Mar 202315.21%10.6110-K filed
31 Mar 202314.45%13.15
14 Apr 202314.15%15.10
28 Apr 202313.61%13.78
15 May 202314.54%9.2210-Q filed, results (8-K)
31 May 202313.14%8.89
15 Jun 202312.51%9.52
30 Jun 202312.94%9.34
14 Jul 202313.11%15.13
31 Jul 202312.94%16.21
15 Aug 202313.46%8.1110-Q filed, results (8-K)
31 Aug 202313.22%9.96
15 Sep 202314.51%6.55
29 Sep 202315.79%9.77
13 Oct 202317.16%11.84
31 Oct 202318.85%7.68
15 Nov 202318.07%1.91results (8-K), 10-Q filed
30 Nov 20239.39%1.45
15 Dec 202310.59%2.43
29 Dec 20239.89%4.44

See also: SkinHealth Systems Inc. Class's full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.